Latest News about Parkinson’s Disease
Recent news which mentions Parkinson’s Disease
Edward L. Weidenfeld, Reagan Attorney & DC Socialite Who Went From Capitol Hill To Cannabis Entrepreneur Dies At 79
January 10, 2023
From Benzinga
PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease
September 17, 2022
Tickers
PHRRF
From Benzinga
AbbVie Walks Away From Parkinson's Drug Pact With BioArctic
April 20, 2022
Tickers
ABBV
From Benzinga
Prothena Highlinghts New Preclinical Data For Alzheimer's, Parkinson's Vaccine Programs
March 16, 2022
Tickers
PRTA
From Benzinga
Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs
March 15, 2022
Tickers
GANX
From Benzinga
Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data
November 10, 2021
Tickers
YMTX
From Benzinga
EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs Placebo
October 05, 2021
Tickers
ANVS
From Benzinga
Stealth Bio Posts Encouraging Preclinical Data In Parkinson's Animal Studies
September 23, 2021
Tickers
MITO
From Benzinga
Gain Therapeutics' Gaucher, Parkinson's Candidate Shows Potential In Patient-Derived iPSC Study
September 08, 2021
Tickers
GANX
From Benzinga
Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial
August 26, 2021
Tickers
AMRX
From Benzinga
AbbVie, Mission Therapeutics Pick Alzheimer's & Parkinson's Targets In Neurodegenerative Disease Collaboration
August 09, 2021
Tickers
ABBV
From Benzinga
Clene's Stock Gain As Its Nanotherapeutic Improves Energy Production, Brain Utilization In Patients With Parkinson's, Multiple Sclerosis
August 05, 2021
Tickers
CLNN
From Benzinga
IBM, Michael J. Fox Foundation Using Artificial Intelligence To Fight Parkinson's Disease
July 29, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.